Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of “Hold” from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.50.

A number of analysts have recently weighed in on PGEN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Wall Street Zen downgraded Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Zacks Research lowered Precigen from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 22nd. Finally, HC Wainwright boosted their price target on shares of Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a report on Friday, November 14th.

Precigen Trading Up 4.0%

Precigen stock opened at $4.93 on Tuesday. The firm’s 50-day moving average is $4.34 and its 200-day moving average is $3.86. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. Precigen has a 1 year low of $1.11 and a 1 year high of $5.22. The company has a market cap of $1.74 billion, a P/E ratio of -3.55 and a beta of 1.07.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $0.67 million. Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%. On average, equities analysts expect that Precigen will post -0.32 earnings per share for the current year.

Insiders Place Their Bets

In other Precigen news, Director Randal J. Kirk sold 1,900,036 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.18, for a total value of $7,942,150.48. Following the sale, the director owned 341,189 shares in the company, valued at approximately $1,426,170.02. This trade represents a 84.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 4,866,329 shares of company stock valued at $20,233,899. Company insiders own 47.10% of the company’s stock.

Institutional Trading of Precigen

Hedge funds have recently added to or reduced their stakes in the business. NBC Securities Inc. bought a new position in shares of Precigen in the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Precigen in the third quarter worth about $39,000. Russell Investments Group Ltd. bought a new position in Precigen in the 3rd quarter valued at about $41,000. Mason Investment Advisory Services Inc. acquired a new position in Precigen during the 4th quarter valued at about $42,000. Finally, Asempa Wealth Advisors bought a new stake in shares of Precigen during the 4th quarter worth about $48,000. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.